INTRODUCING

iStent *inject*® W

EVOLVING DESIGN. ADVANCING PREDICTABILITY.

Featuring a wide flange at its base, the new precision-engineered iStent *inject*® W is designed to optimise stent visualisation and placement, enhance procedural predictability, and increase confidence.



Its advantages are easy to see.

A WIDE FLANGE at the base of iStent *inject* W is designed to:

- Enhance visibility
- Facilitate seamless implantation
- Provide observable positioning confirmation
- Deliver procedural consistency and predictability

REDESIGNED INSERTION SYSTEM optimises control:

- Ergonomic design includes an overall matte finish with molded-in grip texture on the sides, for increased comfort and control
- Enhanced insertion sleeve retraction button facilitates delivery of two iStent *inject* W stents

SYSTEM SPECIFICATIONS

A central inlet and multiple flow outlets optimise flow and collector channel access.



Central Outlet
80 µm dia.

Head
Resides in Schlemm's canal

Side Flow Outlets (4)
50 µm dia.

Thorax
Held by the trabecular meshwork

Wide Flange
Resides in the anterior chamber

Central Inlet
80 µm dia.



iStent *inject* W stents
Made of implant grade titanium and coated with heparin



Insertion tube with window
Optimises visualisation of stents during implantation



Insertion sleeve tip
Reshaped tip for ease of insertion

Built on a proven platform.

Representing the next generation of Glaukos trabecular micro-bypass technology, iStent *inject* W is built on a solid, dependable foundation of proven efficacy and safety in thousands of eyes worldwide.

- **Optimised Outflow:** Two multi-directional stents designed to restore natural outflow
- **Clinically Proven:** Significant IOP reduction across a wide range of clinical studies[1,2]
- **Procedural Elegance:** Predictability and precision to meet the needs of your practice
- **Proven Safety:** Safety profile similar to cataract surgery alone[1]

All with the exceptional customer support you've come to expect from Glaukos.

Contact your Glaukos representative for more information

Australia: Phone 02 8882 4900 • Email Glaukos_CS@Linfox.com
New Zealand: Phone 09 443 5347 • Email Sales@Toomac.co.nz

CE 2797 MR Rx only

Glaukos Australia Pty Ltd
Suite 109 • 12 Corporate Drive • Heatherton • VIC • 3202
www.glaukos.com

GLAUKOS

INDICATION FOR USE. The iStent *inject*® W Trabecular Micro-Bypass System (Model G2-W) is intended to reduce intraocular pressure in adult patients diagnosed with mild to moderate primary open-angle glaucoma (POAG) currently treated with ocular hypotensive medication. The device can be implanted with or without cataract surgery. **CONTRAINDICATIONS.** The device is contraindicated for use in eyes with primary angle closure glaucoma, or secondary angle-closure glaucoma, including neovascular glaucoma, because the device would not be expected to work in such situations, and in patients with retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure. **WARNINGS.** This device has not been studied in patients with uveitic glaucoma. Patients should be informed that placement of the stents, without concomitant cataract surgery in phakic patients, can enhance the formation or progression of cataract. The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. iStent *inject*® is MR-Conditional, meaning that the device is safe for use in a specified MRI environment under specified conditions; please see labelling for details. Physician training is required prior to use and consists of 3 parts: webinar, Didactic session with Glaukos surgical representative and observation of surgical cases by Glaukos representative until implantation proficiency is demonstrated. Do not re-use the stent(s) or injector. **ADVERSE EVENTS.** Postoperative adverse events include but are not limited to: corneal complications including edema, opacification and decompensation, cataract formation (in phakic patients), posterior capsule opacification, stent obstruction, intraocular inflammation (non-preexisting), BCVA loss and IOP increase requiring management with oral or intravenous medications or surgical intervention. Please refer to Directions for Use for additional adverse event information. **CAUTION:** Please reference the Directions For Use labelling for a complete list of contraindications, warnings and adverse events. **REFERENCES:** 1. iStent *inject*® Trabecular Micro-Bypass System: Directions for Use, Part # 45-0176. 2. Hengerer FH. Personal experience with second-generation trabecular micro-bypass stents in combination with cataract surgery in patients with glaucoma: 3-year follow-up. ASCRS 2018 Presentation.